Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key product lines include joint health (ORTHOVISC, MONOVISC), ophthalmic viscoelastics (AMVISC), veterinary products (HYVISC), and aesthetic dermatology (ELEVESS). The company is currently constructing a new manufacturing facility in Bedford, Massachusetts, with validation expected in 2009 and operations planned for 2010.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenue | $9,200,324 | $8,548,779 |
| Net Income | $522,720 | $617,558 |
| Diluted EPS | $0.05 | $0.05 |
| Operating Cash Flow | ($1,098,366) | ($1,383,514) |
| Cash and Equivalents (End of Period) | $40,426,703 | $38,953,354 |
| Total Debt Outstanding | $15,600,000 | $16,000,000 |
| Product Gross Margin | 62.3% | 59.1% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 7.6% year-over-year, driven primarily by an 8.3% increase in product revenue.
- Segment Performance:
- Joint Health: Revenue increased 24.9% to $5.15 million, now representing 60% of total product revenue. Growth was driven by domestic sales increases (11.4%) and significant international expansion (78.0%).
- Ophthalmic: Revenue decreased 12.4% to $2.65 million, attributed to order timing and inventory planning by partners (primarily Bausch & Lomb).
- Veterinary: Revenue decreased 9.0% to $637,335 due to order timing.
- Aesthetics: Revenue increased significantly to $50,094 from $3,000, following the termination of a distribution agreement with Artes Medical and a shift to direct marketing.
- Profitability: Net income decreased 15.4% to $522,720. This decline was primarily due to a 45.5% increase in Research & Development (R&D) expenses ($2.19M vs $1.51M) related to clinical trials for MONOVISC, ELEVESS, and CINGAL, and a 99.2% drop in net interest income due to lower interest rates.
- Capital Expenditures: Investing cash outflows increased to $1.27 million (from $55k in 2008) due to continued spending on the new Bedford facility construction.
Outlook, Risks, and Management Commentary
- Guidance and Outlook:
- Management expects joint health product sales to increase in 2009 compared to 2008.
- Ophthalmic and Veterinary sales are expected to remain relatively flat in 2009.
- R&D expenses are expected to increase in absolute dollars due to pipeline development but decrease as a percentage of revenue.
- General and administrative expenses are expected to increase for the remainder of 2009.
- Capital Projects: The new Bedford facility project is approximately $32 million total; $30 million has been spent through March 31, 2009. The company expects to occupy the existing facility through the end of 2009 and begin manufacturing at the new facility in early 2010.
- Regulatory Risks: The company received an FDA Warning Letter in July 2008 regarding its Woburn facility. While the FDA indicated responses were sufficient in September 2008, discussions are ongoing to clear the letter. Failure to comply could have a material adverse effect.
- Legal Contingencies: An ongoing trademark opposition by Colbar Lifescience (a J&J subsidiary) regarding the ELEVESS trademark. The company believes the claim is without merit and is exploring settlement. No impairment of the ELEVESS intangible asset ($921,569) has been recorded.
- Liquidity: The company maintains a strong cash position ($40.4M) and has a term loan of $15.6M with Bank of America. Quarterly principal payments of $400,000 are required.
Investor Verification Checklist
- Facility Validation: Verify the timeline and success of FDA validation for the new Bedford facility, as this is critical for future manufacturing capacity.
- Joint Health Growth: Confirm the sustainability of the 24.9% growth in joint health revenue, particularly the international expansion.
- R&D Pipeline: Monitor progress on clinical trials for MONOVISC (U.S.) and CINGAL, which are driving increased R&D spend.
- Trademark Dispute: Track the resolution of the ELEVESS trademark opposition, as it impacts the valuation of the intangible asset and future aesthetic product commercialization.
- Customer Concentration: Note that six customers represented 89% of accounts receivable as of March 31, 2009, with DePuy Mitek and Bausch & Lomb being significant partners.